The immunology of epstein-barr virus-induced disease

Annual Review of Immunology

Volumn 33, Issue , 2015, Pages 787-821

  Taylor, Graham S ^a   Long, Heather M ^a   Brooks, Jill M ^a   Rickinson, Alan B ^a   Hislop, Andrew D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adaptive immunity; Autoimmunity; Immunodeficiency; Immunotherapy; Innate immunity; Malignancy

Indexed keywords

X LINKED INHIBITOR OF APOPTOSIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ADOLESCENCE; ANTIBODY RESPONSE; ARTICLE; ASYMPTOMATIC INFECTION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CHRONIC DISEASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; ERYTHROPHAGOCYTOSIS; GENETIC SUSCEPTIBILITY; GRAFT RECIPIENT; HOST; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; IMMUNOPATHOLOGY; INFECTION RISK; INNATE IMMUNITY; LYMPHATIC SYSTEM; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEOSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PATHOGENESIS; PERSISTENT INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DEFICIENCY; VACCINATION; VIRUS CARRIER; X CHROMOSOME LINKED DISORDER; ANIMAL; COMPLICATION; EPSTEIN-BARR VIRUS INFECTIONS; HETEROZYGOTE; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOPROLIFERATIVE DISORDERS; PHYSIOLOGY; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; CARRIER STATE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, INNATE; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84927652740     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032414-112326     Document Type: Article

References (246)

1. LongneckerL,Kieff E, Cohen JI. 2013. Epstein-Barr virus. In Fields Virology, ed.DMKnipe,PMHowley, JI Cohen, DE Griffith, RA Lamb, MA Martin, V Racaniello, B Roizman, pp. 1898-959. Philadelphia: LippincottWilliams & Wilkins
2. Ascherio A, Munger KL. 2010. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence. Clin. Exp. Immunol. 160:120-24
3. Rickinson AB. 2014. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin. Cancer Biol. 26:99-115
4. Wang F. 2013. Nonhuman primate models for Epstein-Barr virus infection. Curr. Opin. Virol. 3:233-37
5. Chatterjee B, Leung CS, Münz C. 2014. Animal models of Epstein Barr virus infection. J. Immunol. Methods 410:80-87
6. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. 2013. The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 3:227-32
7. Kelly GL, LongHM, Stylianou J, ThomasWA,LeeseA, et al. 2009. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLOS Pathog. 5:e1000341
8. Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R. 2012. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLOS Pathog. 8:e1002704
9. Abbott RJ, Quinn LL, Leese AM, Scholes HM, Pachnio A, Rickinson AB. 2013. CD8+ T cell responses to lyticEBVinfection: late antigen specificities as subdominant components of the total response. J. Immunol. 191:5398-409
10. Luzuriaga K, Sullivan JL. 2010. Infectious mononucleosis. N. Engl. J. Med. 362:1993-2000
11. BalfourHHJr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, et al. 2013. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 207:80-88
12. Hoshino Y, Nishikawa K, Ito Y, Kuzushima K, Kimura H. 2011. Kinetics of Epstein-Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis. J. Clin. Virol. 50:244.46
13. Azzi T, Lnunemann A,Murer A, Ueda S, Bleziat V, et al. 2014. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124:2533.43
14. Williams H, McAulay K, Macsween KF, Gallacher NJ, Higgins CD, et al. 2005. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 129:266.74
15. Zhang Y,Wallace DL, de Lara CM, Ghattas H, Asquith B, et al. 2007. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121:258.65
16. Chijioke O,Muller A, Feederle R, BarrosMHM, Krieg C, et al. 2013. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 5:1489.98
17. Strowig T, Brilot F, Arrey F, Bougras G, Thomas D, et al. 2008. Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-α. PLOS Pathog. 4:e27
18. Lnunemann A, Vanoaica LD, Azzi T, Nadal D, Munz C. 2013. A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J. Immunol. 191:4989.95
19. Gaudreault E, Fiola S, Olivier M, Gosselin J. 2007. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J. Virol. 81:8016.24
20. Fiola S,Gosselin D, Takada K, Gosselin J. 2010. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J. Immunol. 185:3620.31
21. Quan TE,Roman RM,Rudenga BJ, Holers VM,Craft JE. 2010. Epstein-Barr virus promotes interferon-αproduction by plasmacytoid dendritic cells. Arthritis Rheum. 62:1693.701
22. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, et al. 2010. Functional delivery of viral miRNAs via exosomes. PNAS 107:6328.33
23. IwakiriD,ZhouL, Samanta M, MatsumotoM, Ebihara T, et al. 2009. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor. J. Exp. Med. 206:2091.99
24. vanGentM, Braem SG, de Jong A,Delagic N, Peeters JG, et al. 2014. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with Toll-like receptor signaling. PLOS Pathog. 10:e1003960
25. Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A. 2010. Toll-like receptor agonists synergistically increase proliferation and activation of B cells by Epstein-Barr virus. J. Virol. 84:3612.23
26. Hoebe EK, Le Large TYS,Greijer AE,Middeldorp JM. 2013. BamHI-A rightward frame 1, an Epstein. Barr virus-encoded oncogene and immune modulator. Rev. Med. Virol. 23:367.83
27. Ohashi M, Fogg MH, Orlova N, Quink C, Wang F. 2012. An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection. PLOS Pathog. 8:e1003095
28. Guerrero-Ramos A, Patel M, Kadakia K, Haque T. 2014. Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis. Clin. Vaccine Immunol. 21:817.23
29. Henle W, Henle G, Andersson J, Ernberg I, Klein G, et al. 1987. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. PNAS 84:570.74
30. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25:587.617
31. Rowe M, Zuo J. 2010. Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect. 12:173.81
32. Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, et al. 2014. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. PLOS Pathog. 10:e1004322
33. Rickinson AB, Long HM, Palendira U, Munz C, Hislop AD. 2014. Cellular immune controls over Epstein.Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol. 35:159.69
34. Hislop AD, KuoM,Drake-Lee AB, Akbar AN, Bergler W, et al. 2005. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J. Clin. Investig. 115:2546.55
35. Apcher S, Komarova A, Daskalogianni C, Yin Y,Malbert-Colas L, Fahraeus R. 2009. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen. J. Virol. 83:1289-98
36. Apcher S, Daskalogianni C, Manoury B, Fahraeus R. 2010. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PLOS Pathog. 6:e1001151
37. Tellam JT, Lekieffre L, Zhong J, Lynn DJ, Khanna R. 2012. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1. PLOS Pathog. 8:e1003112
38. Murat P, Zhong J, Lekieffre L, Cowieson NP, Clancy JL, et al. 2014. G-quadruplexes regulate Epstein-Barr virus-encoded nuclear antigen 1 mRNA translation. Nat. Chem. Biol. 10:358-64
39. Blake N, Haigh T, Shaka'a G, Croom-Carter D, Rickinson A. 2000. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165:7078-87
40. Callan MF, Fazou C, Yang H, Rostron T, Poon K, et al. 2000. CD8+ T-cell selection, function, and death in the primary immune response in vivo. J. Clin. Investig. 106:1251-61
41. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. 2008. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 111:1420-27
42. Balfour HH Jr, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, et al. 2005. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J. Infect. Dis. 192:1505-12
43. Fafi-Kremer S, Morand P, Brion JP, Pavese P, BaccardM, et al. 2005. Long-term shedding of infectious Epstein-Barr virus after infectious mononucleosis. J. Infect. Dis. 191:985-89
44. Catalina MD, Sullivan JL, Bak KR, Luzuriaga K. 2001. Differential evolution and stability of epitopespecific CD8+ T cell responses in EBV infection. J. Immunol. 167:4450-57
45. Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, et al. 2005. Differential targeting and shifts in the immunodominance of Epstein-Barr virus-specific CD8 and CD4 T cell responses during acute and persistent infection. J. Infect. Dis. 192:1513-24
46. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. 2002. Epitope-specific evolution of human CD8+ T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893-905
47. Odumade OA, Knight JA, Schmeling DO, Masopust D, Balfour HH Jr, Hogquist KA. 2012. Primary Epstein-Barr virus infection does not erode preexisting CD8+ T cell memory in humans. J. Exp. Med. 209:471-78
48. Lelic A, Verschoor CP, Ventresca M, Parsons R, Evelegh C, et al. 2012. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLOS Pathog. 8:e1003076
49. Klarenbeek PL, Remmerswaal EB, ten Berge IJ, Doorenspleet ME, van Schaik BD, et al. 2012. Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years. PLOS Pathog. 8:e1002889
50. Iancu EM, Gannon PO, Laurent J, Gupta B, Romero P, et al. 2013. Persistence of EBV antigenspecific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients. PLOS ONE 8:e78686
51. Sulik A, Oldak E, Kroten A, Lipska A, Radziwon P. 2014. Epstein-Barr virus effect on frequency of functionally distinct T cell subsets in children with infectious mononucleosis. Adv. Med. Sci. 59:227-31
52. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, et al. 2003. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198:903-11
53. Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K. 2003. Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol. 170:2590-98
54. LongHM, ChagouryOL, Leese AM, Ryan GB, James E, et al. 2013.MHCII tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J. Exp. Med. 210:933-49
55. Miyawaki T, Kasahara Y, Kanegane H, Ohta K, Yokoi T, et al. 1991. Expression of CD45R0 (UCHL1) byCD4+ andCD8+ Tcells as a sign of in vivo activation in infectious mononucleosis. Clin. Exp. Immunol. 83:447.51
56. Long HM, Leese AM, Chagoury OL, Connerty SR, Quarcoopome J, et al. 2011. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J. Immunol. 187:92.101
57. Mautner J, BornkammGW. 2012. The role of virus-specific CD4+ Tcells in the control of Epstein-Barr virus infection. Eur. J. Cell Biol. 91:31.35
58. Ning RJ, Xu XQ, Chan KH, Chiang AK. 2011. Long-term carriers generate Epstein.Barr virus (EBV)-specific CD4+ and CD8+ polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins. Immunology 134:161.71
59. Leung CS, Maurer MA,Meixlsperger S, Lippmann A, Cheong C, et al. 2013. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 121:1584.94
60. MunzC, BickhamKL, Subklewe M, TsangML, Chahroudi A, et al. 2000. HumanCD4+ Tlymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp.Med. 191:1649.60
61. Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, et al. 2001. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses. J. Virol. 75:8649.59
62. Scherrenburg J, Piriou E, Nanlohy NM, van Baarle D. 2008. Detailed analysis of Epstein.Barr virusspecificCD4 + andCD8+ Tcell responses during infectious mononucleosis. Clin. Exp. Immunol. 153:231. 39
63. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB. 2006. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J. Immunol. 177:3746.56
64. LeungCS, HaighTA, Mackay LK,Rickinson AB, Taylor GS. 2010. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. PNAS 107:2165.70
65. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, et al. 2005. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593.96
66. Wingate PJ, McAulay KA, Anthony IC, Crawford DH. 2009. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection. J. Med. Virol. 81:870.77
67. Clardenas Sierra D, Vlelez Colmenares G, Orfao deMatos A, Fiorentino Glomez S, Quijano Glomez SM. 2014. Age-associated Epstein.Barr virus-specific T cell responses in seropositive healthy adults. Clin. Exp. Immunol. 177:320.32
68. Nikiforow S, Bottomly K, Miller G, Munz C. 2003. Cytolytic CD4+-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77:12088.104
69. Khanna R, Burrows SR, Thomson SA, Moss DJ, Cresswell P, et al. 1997. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specificCTLs. J. Immunol. 158:3619. 25
70. Zuo J, Rowe M. 2012. Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway. Viruses 4:1335.53
71. Rostgaard K, Wohlfahrt J, Hjalgrim H. 2014. A genetic basis for infectious mononucleosis: evidence from a family study of hospitalized cases in Denmark. Clin. Infect. Dis. 58:1684.89
72. Hwang AE, Hamilton AS, Cockburn MG, Ambinder R, Zadnick J, et al. 2012. Evidence of genetic susceptibility to infectious mononucleosis: a twin study. Epidemiol. Infect. 140:2089.95
73. Helminen M, Lahdenpohja N, Hurme M. 1999. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J. Infect. Dis. 180:496.99
74. Vollmer-Conna U, Piraino BF, Cameron B,DavenportT,Hickie I, et al. 2008. Cytokine polymorphisms have a synergistic effect on severity of the acute sickness response to infection. Clin. Infect. Dis. 47:1418.25
75. Hatta K, Morimoto A, Ishii E, Kimura H, Ueda I, et al. 2007. Association of transforming growth factor-β1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases. Haematologica 92:1470.74
76. Clute SC, Watkin LB,CornbergM,Naumov YN, Sullivan JL, et al. 2005. Cross-reactive influenza virus. specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus.associated infectious mononucleosis. J. Clin. Investig. 115:3602.12
77. Biggar RJ, Henle G, Bocker J, Lennette ET, Fleisher G, Henle W. 1978. Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. Int. J. Cancer 22:244.50
78. Silins SL, Sherritt MA, Silleri JM, Cross SM, Elliott SL, et al. 2001. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 98:3739.44
79. Imashuku S. 2002. Clinical features and treatment strategies of Epstein.Barr virus-associated hemophagocytic lymphohistiocytosis. Crit. Rev. Oncol. Hematol. 44:259.72
80. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, et al. 2012. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119:673.86
81. FoxCP, Shannon-LoweC,RoweM. 2011. Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2:8
82. Sugaya N, Kimura H, Hara S, Hoshino Y, Kojima S, et al. 2004. Quantitative analysis of Epstein-Barr virus (EBV)-specificCD8+ Tcells in patients with chronic activeEBVinfection. J. Infect. Dis. 190:985.88
83. Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, et al. 2013. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult. Scler. 19:162.66
84. Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, et al. 2006. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67:2063.65
85. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A. 2011. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 17:1185.93
86. Thacker EL, Mirzaei F, Ascherio A. 2006. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59:499.503
87. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, et al. 2002. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3:940.43
88. Lnunemann JD, Edwards N, Muraro PA,Hayashi S, Cohen JI, et al. 2006. Increased frequency and broadened specificity of latent EBVnuclear antigen-1-specificTcells in multiple sclerosis. Brain 129:1493.506
89. Lnunemann JD, Jel.cilc I, Roberts S, Lutterotti A, Tackenberg B, et al. 2008. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-αand IL-2. J. Exp. Med. 205:1763.73
90. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, et al. 2007. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204:2899.912
91. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, et al. 2012. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 78:15.23
92. Lassmann H, Niedobitek G, Aloisi F,Middeldorp JM. 2011. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue.report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134:2772.86
93. Pender MP, Csurhes PA, Lenarczyk A, Pfluger CMM, Burrows SR. 2009. Decreased T cell reactivity to Epstein.Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J. Neurol.Neurosurg. Psychiatry 80:498.505
94. Lindsey JW, Hatfield LM. 2010. Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity. J. Neuroimmunol. 229:238.42
95. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, et al. 2008. Strong EBV-specificCD8+ T-cell response in patients with early multiple sclerosis. Brain 131:1712.21
96. Jaquiery E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, et al. 2010. Intrathecal immune responses to EBV in early MS. Eur. J. Immunol. 40:878.87
97. Tracy SI, Kakalacheva K, Lnunemann JD, Luzuriaga K, Middeldorp J, Thorley-Lawson DA. 2012. Persistence of Epstein-Barr virus in self-reactive memory B cells. J. Virol. 86:12330.40
98. van Sechel AC, Bajramovic JJ, van Stipdonk MJB, Persoon-Deen C, Geutskens SB, van Noort JM. 1999. EBV-induced expression and HLA-DR-restricted presentation by human B cells of αB-crystallin, a candidate autoantigen in multiple sclerosis. J. Immunol. 162:129.35
99. James JA, Robertson JM. 2012. Lupus and Epstein-Barr. Curr. Opin. Rheumatol. 24:383.88
100. Moon UY, Park SJ, Oh ST, KimWU, Park SH, et al. 2004. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res. Ther. 6:R295.302
101. Larsen M, SauceD,Deback C, Arnaud L, Mathian A, et al. 2011. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLOS Pathog. 7:e1002328
102. James JA, Neas BR, Moser KL, Hall T, Bruner GR, et al. 2001. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 44:1122.26
103. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. 1997. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J. Clin. Investig. 100:3019.26
104. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11:85.89
105. Parvaneh N, Filipovich AH, Borkhardt A. 2013. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br. J. Haematol. 162:573.86
106. Tangye SG. 2014. XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J. Clin. Immunol. 34:772.79
107. Cannons JL,Tangye SG, Schwartzberg PL. 2011.SLAMfamily receptors andSAPadaptors in immunity. Annu. Rev. Immunol. 29:665.705
108. Katz G, Krummey SM, Larsen SE, Stinson JR, Snow AL. 2014. SAP facilitates recruitment and activation of LCK at NTB-A receptors during restimulation-induced cell death. J. Immunol. 192:4202.9
109. Cannons JL,Wu JZ, Gomez-Rodriguez J,Zhang J, Dong B, et al. 2010. Biochemical and genetic evidence for a SAP-PKC-α interaction contributing to IL-4 regulation. J. Immunol. 185:2819.27
110. Zhao F, Cannons JL, Dutta M, Griffiths GM, Schwartzberg PL. 2012. Positive and negative signaling throughSLAMreceptors regulate synapse organization and thresholds of cytolysis. Immunity 36:1003.16
111. Kageyama R, Cannons JL, Zhao F, Yusuf I, Lao C, et al. 2012. The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. Immunity 36:986.1002
112. Dong Z, Davidson D, Perez-Quintero LA, Kurosaki T, Swat W, Veillette A. 2012. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36:974.85
113. Parolini S, Bottino C, Falco M, AugugliaroR,Giliani S, et al. 2000. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus.infected cells. J. Exp. Med. 192:337.46
114. Bottino C, Falco M, Parolini S, Marcenaro E, Augugliaro R, et al. 2001. NTB-A, a novel SH2D1Aassociated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus. infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. 194:235.46
115. SharifiR, Sinclair JC,Gilmour KC, Arkwright PD, KinnonC, et al. 2004. SAPmediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 103:3821.27
116. Duprle L, Andolfi G, Tangye SG, Clementi R, Locatelli F, et al. 2005. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 105:4383.89
117. Ma CS,HareNJ, Nichols KE, Duprle L, Andolfi G, et al. 2005. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J. Clin. Investig. 115:1049.59
118. Hislop AD, Palendira U, Leese AM, Arkwright PD, Rohrlich PS, et al. 2010. Impaired Epstein-Barr virus.specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family.positive B-cell targets. Blood 116:3249.57
119. PalendiraU, Low C, Chan A, Hislop AD,HoE, et al. 2011. Molecular pathogenesis ofEBVsusceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLOS Biol. 9:e1001187
120. Cannons JL,QiH,LuKT, Dutta M, Gomez-Rodriguez J, et al. 2010. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 32:253.65
121. Palendira U, Low C, Bell AI, Ma CS, Abbott RJ, et al. 2012. Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. J. Exp. Med. 209:913.24
122. Rigaud S, Fondanèche MC, Lambert N, Pasquier B, Mateo V, et al. 2006. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444:110.14
123. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, et al. 1996. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379:349.53
124. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300.4
125. Krieg A, Correa RG, Garrison JB, Le Negrate G,Welsh K, et al. 2009. XIAP mediates NOD signaling via interaction with RIP2. PNAS 106:14524.29
126. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, et al. 2012. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol. Cell 46:746.58
127. Chung BK, Tsai K, Allan LL, Zheng DJ, Nie JC, et al. 2013. Innate immune control of EBV-infected B cells by invariant natural killer T cells. Blood 122:2600.8
128. Lopez-Granados E, Stacey M, Kienzler AK, Sierro S, Willberg CB, et al. 2014. A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein.Barr virus-specific T cells. Clin. Exp. Immunol. 178:470.82
129. Rigaud S, Lopez-Granados E, Sibleril S, Gloire G, Lambert N, et al. 2011. Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG. Blood 118:252.61
130. Filipovich AH, Zhang K, Snow AL, Marsh RA. 2010. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood 116:3398.408
131. Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, et al. 2011. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 117:1522.29
132. Orange JS. 2013. Natural killer cell deficiency. J. Allergy Clin. Immunol. 132:515.25
133. de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne AEGK, et al. 1996. Identification of an unusual Fcαreceptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 88:3022.27
134. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. 1996. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 103:408.13
135. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, et al. 2012. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J. Clin. Investig. 122:3769.80
136. Eidenschenk C, Dunne J, Jouanguy E, Fourlinnie C, Gineau L, et al. 2006. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome. Am. J. Hum. Genet. 78:721.27
137. Gineau L, Cognet C, Kara N, Lach FP, Dunne J, et al. 2012. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Investig. 122:821.32
138. Hughes CR, Guasti L, Meimaridou E, Chuang CH, Schimenti JC, et al. 2012. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J. Clin. Investig. 122:814.20
139. Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, et al. 2014. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123:809.21
140. Biron CA, Byron KS, Sullivan JL. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320:1731.35
141. Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, et al. 2013. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood 121:2669.77
142. McClain KL, Leach CT, Jenson HB, Joshi VV, Pollock BH, et al. 1995. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N. Engl. J. Med. 332:12.18
143. Hussein K, Maecker-Kolhoff B, Donnerstag F, Laenger F, Kreipe H, Jonigk D. 2013. Epstein-Barr virus-associated smooth muscle tumours after transplantation, infection with human immunodeficiency virus and congenital immunodeficiency syndromes. Pathobiology 80:297.301
144. Shaw RK, Issekutz AC, Fraser R, Schmit P, Morash B, et al. 2012. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 119:4009.12
145. Spritz RA. 1998. Genetic defects in Chediak-Higashi syndrome and the beige mouse. J. Clin. Immunol. 18:97.105
146. Kaplan J, De Domenico I, Ward DM. 2008. Chediak-Higashi syndrome. Curr. Opin. Hematol. 15:22.29
147. OgimiC,Tanaka R, AraiT,Kikuchi A, Hanada R, Oh-IshiT. 2011. Rituximab and cyclosporine therapy for accelerated phase Chediak-Higashi syndrome. Pediatr. Blood Cancer 57:677.80
148. Greenspan JS, Greenspan D, Lennette ET, Abrams DI, Conant MA, et al. 1985. Replication of Epstein-Barr virus within the epithelial cells of oralghairyh leukoplakia, an AIDS-associated lesion. N. Engl. J. Med. 313:1564.71
149. Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, Matthews HF, et al. 2011. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 475:471.76
150. Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, et al. 2013. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341:186.91
151. Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. 2014. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123:2148.52
152. Moshous D, Martin E, CarpentierW,LimA,Callebaut I, et al. 2013. Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J. Allergy Clin. Immunol. 131:1594.603
153. Stray-Pedersen A, Jouanguy E, Crequer A, Bertuch AA, Brown BS, et al. 2014. Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy. J. Clin. Immunol. 34:871.90
154. Moshous D, Pannetier C, de Chasseval R, le Deist F, Cavazzana-Calvo M, et al. 2003. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J. Clin. Investig. 111:381.87
155. Enders A, Fisch P, Schwarz K, Duffner U, Pannicke U, et al. 2006. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J. Immunol. 176:5060.68
156. Abdollahpour H, AppaswamyG,KotlarzD,Diestelhorst J, Beier R, et al. 2012. The phenotype of human STK4 deficiency. Blood 119:3450.57
157. NehmeNT, Pachlopnik Schmid J, Debeurme F, Andre-Schmutz I, Lim A, et al. 2012. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 119:3458.68
158. Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, et al. 2009. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J. Clin. Investig. 119:1350.58
159. Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, et al. 2011. IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach. Haematologica 96:472.76
160. Linka RM, Risse SL, Bienemann K, Werner M, Linka Y, et al. 2012. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. Leukemia 26:963.71
161. Angulo I, Vadas O, Garccon F, Banham-Hall E, Plagnol V, et al. 2013. Phosphoinositide 3-kinase αgene mutation predisposes to respiratory infection and airway damage. Science 342:866.71
162. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, et al. 2014. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110αresult in Tcell senescence and human immunodeficiency. Nat. Immunol. 15:88.97
163. vanMontfrans JM, Hoepelman AIM,Otto S, vanGijnM, van de Corput L, et al. 2012. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J. Allergy Clin. Immunol. 129:787.93.e6
164. Salzer E,Daschkey S, Choo S,Gombert M, Santos-Valente E, et al. 2013. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. Haematologica 98:473-78
165. Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH. 1999. X-linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J. Virol. 73:1555-64
166. VegsoG,Hajdu M, SebestyenA. 2011. Lymphoproliferative disorders after solid organ transplantation- classification, incidence, risk factors, early detection and treatment options. Pathol. Oncol. Res. 17:443-54
167. Rasche L, Kapp M, Einsele H, Mielke S. 2014. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 49:163-67
168. NikoobakhtM, Beitollahi J,NikoobakhtN, AlooshM, SahebjameeM, et al. 2011. Evaluation of Epstein-Barr virus load in saliva before and after renal transplantation. Transplant. Proc. 43:540-42
169. Storek J, Geddes M, Khan F, Huard B, Helg C, et al. 2008. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin. Immunopathol. 30:425-37
170. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, et al. 2009. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992-5001
171. Styczynski J, Gil L,Tridello G, Ljungman P, Donnelly JP, et al. 2013. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin. Infect. Dis. 57:794-802
172. Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, et al. 2012. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 14:1258-75
173. Auger S,OrsiniM, Ceballos P, Fegueux N, Kanouni T, et al. 2014. Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival. Eur. J. Haematol. 92:421-28
174. Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, et al. 2003. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 102:839-42
175. D'AveniM, Aissi-Rothe L,VenardV, Salmon A, Falenga A, et al. 2011. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 24:224-32
176. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, et al. 2003. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101:4290-97
177. Opelz G, Dohler B. 2004. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4:222-30
178. Wiesmayr S, Webber SA, Macedo C, Popescu I, Smith L, et al. 2012. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur. J. Immunol. 42:541-50
179. Gotoh K, Ito Y, Ohta R, Iwata S, Nishiyama Y, et al. 2010. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. J. Infect. Dis. 202:461-69
180. Macedo C, Donnenberg A, Popescu I, Reyes J, Abu-Elmagd K, et al. 2005. EBV-specificmemory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transpl. Immunol. 14:109-16
181. Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, et al. 2007. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl. Immunol. 17:203-10
182. Smets F, Latinne D, Bazin H, Reding R, Otte JB, et al. 2002. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73:1603-10
183. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, et al. 2006. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin. Transplant. 20:689-94
184. Swerdlow SH,Webber SA, Chadburn A, Ferry JA. 2008. Post-transplant lymphoproliferative disorders. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed. SJ Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, JWVardiman, pp. 343-49. Lyon, Fr.: IARC
185. Guppy AE, Rawlings E, Madrigal JA, Amlot PL, Barber LD. 2007. A quantitative assay for Epstein-Barr virus-specific immunity shows interferon-γ producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 84:1534-39
186. Richendollar BG, Tsao RE, Elson P, Jin T, Steinle R, et al. 2009. Predictors of outcome in posttransplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk. Lymphoma 50:2005-12
187. Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, et al. 2011. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood 117:4315-22
188. Durand-Panteix S, Farhat M, Youlyouz-Marfak I, Rouaud P, Ouk-Martin C, et al. 2012. B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at bothmRNA and secretory lysosome levels. J. Immunol. 189:181-90
189. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, et al. 2013. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19:3462-73
190. Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, et al. 2014. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 49:280-86
191. Rooney CM, Leen AM, Vera JF, Heslop HE. 2014. T lymphocytes targeting native receptors. Immunol. Rev. 257:39-55
192. Merlo A, Turrini R, Dolcetti R, Zanovello P, Rosato A. 2011. Immunotherapy for EBV-associated malignancies. Int. J. Hematol. 93:281-93
193. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, et al. 2012. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119:2644-56
194. Ricciardelli I, Brewin J, Lugthart G, Albon SJ, Pule M, Amrolia PJ. 2013. Rapid generation of EBVspecific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. Am. J. Transplant. 13:3244-52
195. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, et al. 2013. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121:5113-23
196. Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, et al. 2014. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br. J. Haematol. 167:402-10
197. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, et al. 2013. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 31:39-48
198. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. 2006. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 106:128-35
199. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, et al. 2008. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 22:301-6
200. Ong KW, Teo M, Lee V, Ong D, Lee A, et al. 2009. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin. Cancer Res. 15:5350-58
201. Lee SP, Chan ATC, Cheung ST, Thomas WA, CroomCarter D, et al. 2000. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J. Immunol. 165:573-82
202. Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, et al. 2010. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK-and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116:3695-704
203. Fu T, Voo KS, Wang RF. 2004. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J. Clin. Investig. 114:542.50
204. Paludan C, Bickham K, Nikiforow S, TsangML, Goodman K, et al. 2002. Epstein-Barr nuclear antigen 1-specific CD4+ Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593.603
205. Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, et al. 2008. Epstein.Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein.Barr virus-carrying natural killer and T cells. Cancer Sci. 99:1633.42
206. Fogg MH,Wirth LJ, Posner M,Wang F. 2009. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. PNAS 106:3318.23
207. Moormann AM,HellerKN, ChelimoK,Embury P, Ploutz-SnyderR, et al. 2009. Childrenwith endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-δT cell responses. Int. J. Cancer 124:1721.26
208. Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, et al. 2008. Patients with Epstein Barr viruspositive lymphomas have decreased CD4+ T-cell responses to the viral nuclear antigen. Int. J. Cancer 123:2824.31
209. Piriou E, van Dort K, Nanlohy NM, van Oers MHJ, Miedema F, van Baarle D. 2005. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 106:3166.74
210. Chapman ALN, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. 2001. Epstein-Barr virusspecific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 61:6219.26
211. Lin X, Gudgeon NH, Hui EP, Jia H, Qun X, et al. 2008. CD4 and CD8 T cell responses to tumourassociated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol. Immunother. 57:963.75
212. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, et al. 2006. Expression of LAG-3 by tumorinfiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108:2280.89
213. Niens M, Jarrett RF, Hepkema B, Nolte IM, Diepstra A, et al. 2007. HLA-A.02 is associated with a reduced risk and HLA-A.01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110:3310.15
214. Su WH, Hildesheim A, Chang YS. 2013. Human leukocyte antigens and Epstein.Barr virus-associated nasopharyngeal carcinoma: Old associations offer new clues into the role of immunity in infectionassociated cancers. Front. Oncol. 3:299
215. Huang X, Hepkema B, Nolte I, Kushekhar K, Jongsma T, et al. 2012. HLA-A.02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLOS ONE 7:e31865
216. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, et al. 2009. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765.3775
217. Barros MHM, Vera-Lozada G, Soares FA, Niedobitek G, Hassan R. 2012. Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection. Int. J. Cancer 131:1142.52
218. Morales O, Mrizak D, Francois V, Mustapha R, Miroux C, et al. 2014. Epstein.Barr virus infection induces an increase ofTregulatory type 1 cells in Hodgkin lymphoma patients. Br. J.Haematol. 166:875. 90
219. Assis MC, Campos AH, Oliveira JS, Soares FA, Silva JM, et al. 2012. Increased expression of CD4+CD25+FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil. Med. Oncol. 29:3614.19
220. Baumforth KRN, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, et al. 2008. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am. J. Pathol. 173:195.204
221. Yamamoto R, NishikoriM,KitawakiT, Sakai T, HishizawaM, et al. 2008. PD-1.PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111:3220.24
222. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, et al. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. PNAS 104:13134-39
223. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, et al. 2012. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18:1611-18
224. Parsonage G,Machado LR, Hui JW, McLarnon A, Schmaler T, et al. 2012. CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma. Am. J. Pathol. 180:1215-22
225. Yip WK, Abdullah MA, Yusoff SM, Seow HF. 2009. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced β-chain expression in nasopharyngeal carcinoma patients. Clin. Exp. Immunol. 155:412-22
226. Li J, Huang ZF, Xiong G, Mo HY, Qiu F, et al. 2011. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma. J. Transl. Med. 9:189
227. Klibi J,NikiT, Riedel A, Pioche-Durieu C, Souquere S, et al. 2009. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113:1957-66
228. Cai MB, Han HQ, Bei JX, Liu CC, Lei JJ, et al. 2012. Expression of human leukocyte antigen G is associated with prognosis in nasopharyngeal carcinoma. Int. J. Biol. Sci. 8:891-900
229. Cancer Genome Atlas Res. Netw. 2014. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-9
230. Song HJ, Srivastava A, Lee J, Kim YS, KimKM, et al. 2010. Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139:84-92.e2
231. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, et al. 2013. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLOS Pathog. 9:e1003341
232. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, et al. 2010. Adoptive transfer of EBVspecific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J. Immunother. 33:983-90
233. Chia WK, Teo M, Wang WW, Lee B, Ang SF, et al. 2014. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol. Ther. 22:132-39
234. Smith C, Tsang J, Beagley L, Chua D, Lee V, et al. 2012. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 72:1116-25
235. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, et al. 2014. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32:798-808
236. Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, et al. 2013. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 73:1676-88
237. Taylor GS, Jia H, Harrington K, Lee LW, Turner J, et al. 2014. A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a Phase I trial in UK Patients with EBV-positive cancer. Clin. Cancer Res. 20:5009-22
238. LouisCU, StraathofK, BollardCM, Gerken C, HulsMH,et al. 2009. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 113:2442-50
239. Cohen JI, Fauci AS, Varmus H, Nabel GJ. 2011. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci. Transl. Med. 3:107fs7
240. Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, et al. 2007. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196:1749-53
241. Sashihara J,Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, et al. 2011. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLOS Pathog. 7:e1002308
242. Leruez-Ville M, Seng R, Morand P, Boufassa F, Boue F, et al. 2012. Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma. HIV Med. 13:479-87
243. Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, et al. 2013. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine 31:3039-45
244. Adhikary D, Behrends U, Moosmann A, WitterK,BornkammGW,Mautner J. 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp.Med. 203:995-1006
245. Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA. 1988. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virusinduced malignant lymphomas. J. Med. Virol. 25:189-95
246. Pavlova S, Feederle R, Gartner K, Fuchs W, Granzow H, Delecluse HJ. 2013. An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA. J. Virol. 87:2011-22